Ardelyx, Inc.

NasdaqGM:ARDX

Market Cap

USD 868.50 M

Share Price

USD 3.63

Avg Daily Volume

5,353,574

Change (1 day)

-1.36%

Change (1 year)

-39.70%

Change (YTD)

-28.40%

Ardelyx, Inc. Current Ratio for the Trailing 12 Months (TTM) ending March 31, 2025: 4.24

Ardelyx, Inc. Current Ratio is 4.24 for the Trailing 12 Months (TTM) ending March 31, 2025, a -0.61% change year over year. Current ratio represents the short-term liquidity measurement, showing current assets' coverage of liabilities. Higher ratio implies better ability to meet short-term obligations.
  • Ardelyx, Inc. Current Ratio for the Trailing 12 Months (TTM) ending March 31, 2024 was 4.27, a 83.20% change year over year.
  • Ardelyx, Inc. Current Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 2.33, a -8.20% change year over year.
  • Ardelyx, Inc. Current Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 2.54.
Key data
Date Current Ratio Interest Coverage Ratio Return on Capital Employed (ROCE) Return on Equity (ROE)
Market news
Loading...
NasdaqGM: ARDX

Ardelyx, Inc.

CEO Mr. Michael G. Raab
IPO Date June 19, 2014
Location United States
Headquarters 400 Fifth Avenue
Employees 395
Sector 🏥 Health Care
Industries
Description

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Similar companies

BMRN

BioMarin Pharmaceutical Inc.

USD 54.14

-1.01%

4151.T

Kyowa Kirin Co., Ltd.

USD 17.15

0.68%

ABBOTINDIA.NS

Abbott India Limited

USD 370.22

0.53%

002422.SZ

Sichuan Kelun Pharmaceutical Co., Ltd.

USD 4.89

0.65%

1SXP.F

SCHOTT Pharma AG & Co. KGaA

USD 33.23

0.43%

688336.SS

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd

USD 7.50

-1.27%

1513.HK

Livzon Pharmaceutical Group Inc.

USD 3.68

-1.53%

0867.HK

China Medical System Holdings Limited

USD 1.53

0.34%

002773.SZ

Chengdu Kanghong Pharmaceutical Group Co., Ltd

USD 3.95

-0.35%

GLAND.NS

Gland Pharma Limited

USD 20.73

0.19%

000623.SZ

Jilin Aodong Pharmaceutical Group Co., Ltd.

USD 2.37

-0.26%

600062.SS

China Resources Double-Crane Pharmaceutical Co.,Ltd.

USD 2.61

0.21%

603707.SS

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd

USD 1.50

-1.16%

002019.SZ

Yifan Pharmaceutical Co., Ltd.

USD 1.83

-1.29%

CONCORDBIO.NS

Concord Biotech Limited

USD 21.31

1.01%

9989.HK

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

USD 0.68

-2.74%

002755.SZ

Beijing Aosaikang Pharmaceutical Co., Ltd.

USD 2.22

-3.61%

NEULANDLAB.NS

Neuland Laboratories Limited

USD 140.39

0.47%

300294.SZ

China Resources Boya Bio-pharmaceutical Group Co., Ltd.

USD 3.63

-0.13%

FAE.MC

Faes Farma, S.A.

USD 5.21

-0.90%

LLY

Eli Lilly and Company

USD 792.30

1.83%

ABBV

AbbVie Inc.

USD 185.39

-0.09%

RO.SW

Roche Holding AG

USD 341.12

-1.04%

AZN.L

AstraZeneca PLC

USD 140.14

-0.36%

MRK

Merck & Co., Inc.

USD 79.67

-0.81%

TMO

Thermo Fisher Scientific Inc.

USD 410.65

1.55%

AMGN

Amgen Inc.

USD 280.35

1.03%

PFE

Pfizer Inc.

USD 24.26

-0.21%

GILD

Gilead Sciences, Inc.

USD 105.93

-1.19%

SAN.PA

Sanofi

USD 95.90

-1.25%

BMY

Bristol-Myers Squibb Company

USD 46.68

-0.74%

4519.T

Chugai Pharmaceutical Co., Ltd.

USD 52.21

0.11%

GSK.L

GSK plc

USD 19.07

-0.64%

COR

Cencora, Inc.

USD 292.32

-0.61%

REGN

Regeneron Pharmaceuticals, Inc.

USD 520.29

-0.38%

600276.SS

Jiangsu Hengrui Medicine Co., Ltd.

USD 7.29

-1.15%

HLN.L

Haleon plc

USD 5.22

0.20%

4502.T

Takeda Pharmaceutical Company Limited

USD 30.06

0.25%

4568.T

Daiichi Sankyo Company, Limited

USD 22.75

-2.17%

UCB.BR

UCB SA

USD 196.91

2.58%

3692.HK

Hansoh Pharmaceutical Group Company Limited

USD 3.66

-2.04%

DIVISLAB.NS

Divi's Laboratories Limited

USD 76.80

0.32%

INSM

Insmed Incorporated

USD 104.85

-0.99%

TEVA.TA

Teva Pharmaceutical Industries Limited

USD 17.07

-0.24%

600436.SS

Zhangzhou Pientzehuang Pharmaceutical., Ltd

USD 28.11

-0.09%

FME.DE

Fresenius Medical Care AG & Co. KGaA

USD 55.37

-0.10%

WST

West Pharmaceutical Services, Inc.

USD 221.02

-0.74%

SMMT

Summit Therapeutics Inc.

USD 21.27

1.67%

CIPLA.NS

Cipla Limited

USD 17.67

0.68%

UTHR

United Therapeutics Corporation

USD 285.97

-1.37%

StockViz Staff

June 26, 2025

Any question? Send us an email